BioPremiere Inc.

BioPremiere Inc. is a biopharmaceutical company developing novel, and premium biologics for serious diseases. Our candidate drugs, an EPO-lke protein and the Tetravalent Ig Fusion Protein platform (tetravalent TNFRII-Ig, CTLA4-Ig, LAG3-Ig and CD2-Ig) have a strong IP position, and are in late stage preclinical development.

The BioPremiere team has a strong record of advancing preclinical-stage assets to cinical-stages and clinical proof-of-concept.  Our business model is to de-risk these assets followed by partnering or out-licensing.

News and Events

BioPremiere Inc. has secured the rights for preclinical-stage biologics.

BioPremiere Inc. has attracted seasoned drug development and regulatory affairs proffesionals.